Newron continues to advance the Phase 3 ENIGMA-TRS development program. ENIGMA-TRS 1 enrollment is expected to be completed by mid-October, with topline 12-week data expected in Q1 2027. ENIGMA-TRS 2 ...
Ad hoc announcement pursuant to Art. 53 LR U.S. clinical hold remains in place; study continues in all other countries ...
Newron Pharmaceuticals S.p.A. announced that it has been informed by the U.S. Food and Drug Administration (FDA) that the hold on the enrollment of new patients will remain in place at U.S. sites in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results